Compare SPRO & SWVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | SWVL |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 70.1M |
| IPO Year | 2017 | 2021 |
| Metric | SPRO | SWVL |
|---|---|---|
| Price | $0.94 | $4.82 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.33 | N/A |
| AVG Volume (30 Days) | ★ 320.0K | 31.8K |
| Earning Date | 11-12-2026 | 10-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.95 | $1.30 |
| 52 Week High | $3.08 | $8.48 |
| Indicator | SPRO | SWVL |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 65.62 |
| Support Level | N/A | $3.55 |
| Resistance Level | $1.27 | $8.48 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 3.18 | 72.07 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Swvl Holdings Corp is a technology-driven mobility company providing mass transit solutions. It currently has two offerings: business-to-consumer (B2C) and B2B (marketed as Swvl Business). The company's B2C business utilizes its platform to provide riders with a network of minibuses and other vehicles that operate on fixed and semi-fixed routes throughout and between different cities. Riders can book available seats on vehicles to commute within a city. The Swvl Business caters to corporate customers (as well as schools and municipalities), providing them with transportation solutions for their employees and students. This business also offers transportation management software to clients who operate their own fleet. Geographically, the company generates maximum revenue from Egypt.